RecruitingNCT07419347

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

Retrospective Analysis of Glecaprevir/Pibrentasvir Safety and Concomitant Medications Through Integrated Real-World Data

Sponsor

AbbVie

Enrollment

2,000 participants

Start Date

Feb 27, 2026

Study Type

OBSERVATIONAL

Conditions

Hepatitis C Virus (HCV)

Summary

The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with hepatitis c virus (hcv). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(2)

Vancouver Infectious Diseases Centre /ID# 275313

Vancouver, British Columbia, Canada

St. Clair Medical Clinic /ID# 275334

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07419347

Related Trials

California MEPS Hub

NCT074339853 locations

Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons

NCT071222199 locations